✦ LIBER ✦

447 IL28B POLYMORPHISM IS NOT ASSOCIATED WITH RESPONSE TO CONVENTIONAL INTERFERON TREATMENT AND HBSAG SEROCLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS

✍ Scribed by O. Lada; Q. Zhang; M. Lapalus; R. Moucari; S. De Muynck; M. Martinot-Peignoux; I. Bieche; C. Laouenan; E. Estrabaud; N. Boyer; M. Vidaud; T. Asselah; P. Marcellin

Book ID: 117380659
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 63 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(12)60460-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

IL28B polymorphism is associated with tr

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C

✍ Tarik Asselah; Simon De Muynck; Philippe Broët; Julien Masliah-Planchon; Maud Bl 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 698 KB

Association between IL28B polymorphism a

Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C

✍ Albert Friedrich Stättermayer; Harald Hofer; Peter Ferenci 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 331 KB

Prediction of response to entecavir ther

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels

✍ J. W. Shin; S. W. Jung; B. R. Park; C. J. Kim; J. B. Eum; B. G. Kim; I. D. Jeong 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

IL28B But Not ITPA Polymorphism Is Predi

IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C

✍ Kamatani, N.; Sezaki, H.; Chayama, K.; Hayes, C. N.; Abe, H.; Miki, D.; Ochi, H. 📂 Article 📅 2011 🏛 University of Chicago Press 🌐 English ⚖ 454 KB

820 A FOUR GENE MOLECULAR SIGNATURE IS B

820 A FOUR GENE MOLECULAR SIGNATURE IS BETTER THAN IL28B POLYMORPHISM TO PREDICT TREATMENT RESPONSE TO PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C

✍ T. Asselah; I. Bieche; B. Jardin-Watelet; A. Duces; M. Lapalus; S. De Muynck; E. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Treatment with peginterferon alfa-2a (40

Treatment with peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBEAG positive chronic hepatitis B harboring HBV genotypes B or ‘difficult-to-treat’ genotype C

✍ W.G.E. Cooksley; M.-Y. Lai; T. Piratvisuth; Y.-J. Wang; V. Mahachai; Y.-C. Chao; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 135 KB